Tranexamic acid for trauma: Filling the 'GAP' in evidence

Biswadev Mitra, Stefan M Mazur, Peter Cameron, Stephen Anthony Bernard, Brian James Burns, Anthony N Smith, Stephen Rashford, Mark Fitzgerald, Karen Louise Smith, Russell Lindsay Gruen

Research output: Contribution to journalArticleOther

35 Citations (Scopus)


Following findings of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial, tranexamic acid (TxA) use post trauma is becoming widespread. However, issues of generalisability, applicability and predictability beyond the context of study sites remain unresolved. Internal and external validity of the CRASH-2 trial are currently lacking and therefore incorporation of TxA into routine trauma resuscitation guidelines appears premature. The Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (PATCH)-Trauma study is a National Health and Medical Research Council-funded randomised controlled trial of early administration of TxA in severely injured patients likely to have acute traumatic coagulopathy. The study population chosen has high mortality and morbidity and is potentially most likely to benefit from TxA s known mechanisms of action. This and further trials involving appropriate sample populations are required before evidence based guidelines on TxA use during trauma resuscitation can be developed.
Original languageEnglish
Pages (from-to)194 - 197
Number of pages4
JournalEmergency Medicine Australasia
Issue number2
Publication statusPublished - 2014

Cite this